DaVita (NYSE:DVA) Stock Price Down 3.9% – What’s Next?

DaVita Inc. (NYSE:DVA)’s stock price dropped 3.9% during trading on Tuesday. The stock traded as low as $187.91 and last traded at $179.6140. Approximately 103,555 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 882,677 shares. The stock had previously closed at $187.00.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on DVA shares. Barclays lifted their price target on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Raymond James Financial set a $220.00 price objective on DaVita in a report on Friday, August 7th. UBS Group raised their target price on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Oppenheimer set a $220.00 target price on DaVita in a research note on Friday, August 7th. Finally, Truist Financial lowered their price target on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $233.43.

DaVita Price Performance

The firm has a market cap of $11.28 billion, a price-to-earnings ratio of 14.59, a PEG ratio of 0.49 and a beta of 0.80. The stock has a 50-day moving average price of $180.54 and a 200 day moving average price of $191.07.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%. The business’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities research analysts predict that DaVita Inc. will post 14.57 earnings per share for the current year.

Hedge Funds Weigh In On DaVita

A number of hedge funds have recently modified their holdings of DVA. Berkshire Hathaway Inc purchased a new position in DaVita in the second quarter worth $6,425,269,000. BlackRock Inc. acquired a new stake in DaVita in the second quarter valued at $547,520,000. Dimensional Fund Advisors LP boosted its position in shares of DaVita by 5.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock worth $176,037,000 after purchasing an additional 56,336 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of DaVita during the 2nd quarter worth $145,057,000. Finally, Bank of New York Mellon Corp grew its stake in shares of DaVita by 81.2% during the 1st quarter. Bank of New York Mellon Corp now owns 457,493 shares of the company’s stock worth $70,312,000 after purchasing an additional 204,984 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.